Class of 2012 Abstract / Specific Aims: To evaluate disease- and patient-related characteristics, mortality, and charges associated with non-AIDS defining malignancies (NADM) among inpatient settings in the United States from 2005 to 2009. Methods: This retrospective cohort investigation utilized nationally-representative hospital discharge records from the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (H-CUP) Nationwide Inpatient Sample. Inclusion criteria included adult inpatients ≥18 years with a diagnosis of HIV or AIDS and malignant neoplasms. Multivariate regression analyses were used to assess inpatient mortality and charges. Main Results: Overall, 104,488 were included. Average age associated with each case was 46.9 years (±10.66), with 21.9% cases being female (n=22,868). The mean length of stay was 8.6 days (±10.5) and inpatient mortality occurred in 7.7% of cases (n=8,035). The mean number of procedures performed was 2.3 (±2.5) and the mean number of diagnoses on record was 9.5 (±4.4). Charges for each episode of care averaged $59,483 (±85,748), summing to a national bill of $6.14 billion (2011 dollars) over the five-year course. A higher number of cases were associated with teaching hospitals (74.1%), the south (42%), large metropolitan areas (75.1%), median household income in the 0-25th percentile (41.2%), and Medicaid payers (34.3%). Increased mortality was associated with increased age, increased number of diagnoses and procedures, and the comorbidities of anemia, coagulopathy, lymphoma, and fluid and electrolyte disorders. Conclusions: This investigation of NADMs suggest a considerable clinical and economic burden of illness, summing to a 7.7% inpatient death rate and $1.3 billion in charges per year.

Class of 2011 Abstract / OBJECTIVES: To assess the role of patient, payer, clinical and disease-related factors in charges and mortality among adult inpatient cases of polycythemia vera in the United States from 2004 to 2008. METHODS: This retrospective cohort study utilized hospital discharge records from the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS) five consecutive years from 2004 to 2008. RESULTS: There were a total of 156,490 episodes of care involving polycythemia vera between 2004 and 2008. Average age upon admission was 65.94 years (±16.03), with 56% of cases being male (n=87,662). The mean length of stay was 5.14 days (±5.31) and inpatient mortality occurred in 3.1% of cases (n=4,927). The mean number of procedures performed was 1.43 (±2.08) and the mean number of diagnoses on record was 9.56 (±3.86). Charges for each episode of care averaged $32,620 (±42,801), summing to a national bill of $5.02 billion (2010 dollars) over the five-year time horizon. Higher charges were associated with longer length of stay, larger hospital bed size, urban hospital location, teaching status, increased number of diagnoses and procedures, private payer, Western U.S. region, and higher income bracket. Increased mortality was associated with increased age, increased number of diagnoses and procedures, self pay, payer other than Medicare, Medicaid, private or self, and the comorbidities of congestive heart failure, coagulopathy, and fluid/electrolyte disorders. CONCLUSION: Polycythemia vera is associated with considerable burden of illness.

No description available.

No description available.

Preterm birth (< 37 weeks gestation) is a major health burden for affected children. Although the risk of health problems increases as the gestational age decreases, research in the last decades has revealed that even late preterm infants born at 34-36 weeks gestational age have higher mortality and morbidity than term infants. Because late preterm infants constitute three fourths of preterm infants, they are important from both public health and health policy perspectives. This doctoral thesis sought to answer important knowledge gaps in health service utilization of late preterm infants via three studies. Study A, a systematic review and meta-analysis comparing health service utilizations of late preterm infants with those of term infants, found that late preterm infants had increased hospitalization compared with term infants that persisted from the neonatal period through adolescence. Study B is a cohort study evaluating the re-admissions and emergency department visits by late preterm and term singletons and twins for the first 5 years after birth. Study B demonstrated that late preterm infants had higher re-admission rates than term infants although differences in twins were less pronounced than in singletons. Study C is a population-based cohort study with cost analyses assessing the health care costs and resource utilization related to three different discharge timings of late preterm and term singletons: early (< 48 hours), late (48-71 hours), and very-late (72-95 hours) discharge after birth. Study C found that early discharge was not associated with the reduction of health care cost in late preterm infants, and instead was associated with an increase in the cost in term infants over the first year after birth. These findings are useful for parents, care providers, health policy makers, and guideline developers to provide optimal care for late preterm infants. / Thesis / Doctor of Philosophy (PhD)

Contexte : Les stratégies pharmacologiques pour traiter la schizophrénie reçoivent une attention croissante due au développement de nouvelles pharmacothérapies plus efficaces, mieux tolérées mais plus coûteuses. La schizophrénie est une maladie chronique présentant différents états spécifiques et définis par leur sévérité. Objectifs : Ce programme de recherche vise à: 1) Évaluer les facteurs associés au risque d'être dans un état spécifique de la schizophrénie, afin de construire les fonctions de risque de la modélisation du cours naturel de la schizophrénie; 2) Développer et valider un modèle de Markov avec microsimulations de Monte-Carlo, afin de simuler l'évolution naturelle des patients qui sont nouvellement diagnostiqués pour la schizophrénie, en fonction du profil individuel des facteurs de risque; 3) Estimer le coût direct de la schizophrénie (pour les soins de santé et autres non reliés aux soins de santé) dans la perspective gouvernementale et simuler l’impact clinique et économique du développement d’un traitement dans une cohorte de patients nouvellement diagnostiqués avec la schizophrénie, suivis pendant les cinq premières années post-diagnostic. Méthode : Pour le premier objectif de ce programme de recherche, un total de 14 320 patients nouvellement diagnostiqués avec la schizophrénie ont été identifiés dans les bases de données de la RAMQ et de Med-Echo. Les six états spécifiques de la schizophrénie ont été définis : le premier épisode (FE), l'état de dépendance faible (LDS), l’état de dépendance élevée (HDS), l’état stable (Stable), l’état de bien-être (Well) et l'état de décès (Death). Pour évaluer les facteurs associés au risque de se trouver dans chacun des états spécifiques de la schizophrénie, nous avons construit 4 fonctions de risque en se basant sur l'analyse de risque proportionnel de Cox pour des risques compétitifs. Pour le deuxième objectif, nous avons élaboré et validé un modèle de Markov avec microsimulations de Monte-Carlo intégrant les six états spécifiques de la schizophrénie. Dans le modèle, chaque sujet avait ses propres probabilités de transition entre les états spécifiques de la schizophrénie. Ces probabilités ont été estimées en utilisant la méthode de la fonction d'incidence cumulée. Pour le troisième objectif, nous avons utilisé le modèle de Markov développé précédemment. Ce modèle inclut les coûts directs de soins de santé, estimés en utilisant les bases de données de la Régie de l'assurance maladie du Québec et Med-Echo, et les coûts directs autres que pour les soins de santé, estimés à partir des enquêtes et publications de Statistique Canada. Résultats : Un total de 14 320 personnes nouvellement diagnostiquées avec la schizophrénie ont été identifiées dans la cohorte à l'étude. Le suivi moyen des sujets était de 4,4 (± 2,6) ans. Parmi les facteurs associés à l’évolution de la schizophrénie, on peut énumérer l’âge, le sexe, le traitement pour la schizophrénie et les comorbidités. Après une période de cinq ans, nos résultats montrent que 41% des patients seront considérés guéris, 13% seront dans un état stable et 3,4% seront décédés. Au cours des 5 premières années après le diagnostic de schizophrénie, le coût direct moyen de soins de santé et autres que les soins de santé a été estimé à 36 701 $ canadiens (CAN) (95% CI: 36 264-37 138). Le coût des soins de santé a représenté 56,2% du coût direct, le coût de l'aide sociale 34,6% et le coût associé à l’institutionnalisation dans les établissements de soins de longue durée 9,2%. Si un nouveau traitement était disponible et offrait une augmentation de 20% de l'efficacité thérapeutique, le coût direct des soins de santé et autres que les soins de santé pourrait être réduit jusqu’à 14,2%. Conclusion : Nous avons identifié des facteurs associés à l’évolution de la schizophrénie. Le modèle de Markov que nous avons développé est le premier modèle canadien intégrant des probabilités de transition ajustées pour le profil individuel des facteurs de risque, en utilisant des données réelles. Le modèle montre une bonne validité interne et externe. Nos résultats indiquent qu’un nouveau traitement pourrait éventuellement réduire les hospitalisations et le coût associé aux établissements de soins de longue durée, augmenter les chances des patients de retourner sur le marché du travail et ainsi contribuer à la réduction du coût de l'aide sociale. / Aim: Pharmacological strategies for schizophrenia have received increasing attention due to the development of new therapies more effective, better tolerated but more expensive. Schizophrenia is a chronic illness with various states of illness. Objectives: This research program aimed: 1) to evaluate the factors associated with the risk of being in a specific state of schizophrenia in order to construct the risk functions of the course of schizophrenia modeling; 2) to develop and validate a Markov model with Monte-Carlo micro-simulations in order to simulate the natural course of patients who have been newly diagnosed with schizophrenic based upon the individual risk factors profile; and 3) to estimate the direct healthcare and non-healthcare cost of schizophrenia and to simulate clinical and economic impact of developing a new treatment, in a cohort of patients newly diagnosed with schizophrenia, over the first 5 years following their diagnosis. Methods: For the first objective of this research program, a total of 14,320 newly diagnosed patients with schizophrenia were identified based on data from the RAMQ and Med-Echo databases. Six disorder states of schizophrenia were defined: first episode (FE), low dependency state (LDS), high dependency state (HDS), Stable state (Stable), Well state (Well) and Death state (Death). To evaluate factors associated to the risk of being in each disease state, we constructed 4 risk functions based on the Cox proportional hazard analysis for competing risks. For the second objective, a Markov model with Monte-Carlo microsimulations with the six specific states of schizophrenia was developed and validated. In the model, each subject had his own probabilities of transition between specific states, which were estimated based on the cumulative incidence function. For the third objected, we used the Markov model we previously developed. The model includes direct healthcare costs estimated from the Régie de l’assurance maladie du Québec and Med-Echo databases and direct non-healthcare costs estimated from the surveys and publications of Statistics Canada. Results: A total of 14,320 individuals were identified in the study cohort as newly diagnosed patients with schizophrenia. The mean follow-up of the subjects was of 4.4 (± 2.6) years. The age, the sex, the schizophrenia treatment, and having comorbidities are factors that are associated with the schizophrenia course. After a five-year period, our results show that 41% of patients will be considered as having recovered, 13% will be in stable condition and 3.4% of patients will have died. The mean direct healthcare and non-healthcare cost of schizophrenia over the first 5 years following diagnosis was estimated $36,701 Canadian (CAN) (95% CI: 36,264 to 37,138). The direct healthcare cost accounted for 56.2% of the total cost, welfare assistance for 34.6% and long term care facilities for 9.2%. On the direct healthcare cost, hospitalisation cost accounted for 64.6%, medical cost for 11.4% and drug-related cost for 24%. In the case where a new treatment with 20% increase of effectiveness will be available, the direct healthcare and non-healthcare costs can be reduced up to 14.2%. Conclusion: We have identified factors associated with the schizophrenia’s specific states, The Markov model we have developed is the first Canadian model incorporating transition probabilities adjusted for individual risk factor profiles using real-life data. The model shows a good internal and external validity. Based on the cost estimates, our results indicate that a new treatment could possibly reduce hospitalization and long-term care facility costs while potentially enabling patients to return to active employment that would in turn contribute to the reduction of the welfare assistance cost.

Contexte : Les stratégies pharmacologiques pour traiter la schizophrénie reçoivent une attention croissante due au développement de nouvelles pharmacothérapies plus efficaces, mieux tolérées mais plus coûteuses. La schizophrénie est une maladie chronique présentant différents états spécifiques et définis par leur sévérité. Objectifs : Ce programme de recherche vise à: 1) Évaluer les facteurs associés au risque d'être dans un état spécifique de la schizophrénie, afin de construire les fonctions de risque de la modélisation du cours naturel de la schizophrénie; 2) Développer et valider un modèle de Markov avec microsimulations de Monte-Carlo, afin de simuler l'évolution naturelle des patients qui sont nouvellement diagnostiqués pour la schizophrénie, en fonction du profil individuel des facteurs de risque; 3) Estimer le coût direct de la schizophrénie (pour les soins de santé et autres non reliés aux soins de santé) dans la perspective gouvernementale et simuler l’impact clinique et économique du développement d’un traitement dans une cohorte de patients nouvellement diagnostiqués avec la schizophrénie, suivis pendant les cinq premières années post-diagnostic. Méthode : Pour le premier objectif de ce programme de recherche, un total de 14 320 patients nouvellement diagnostiqués avec la schizophrénie ont été identifiés dans les bases de données de la RAMQ et de Med-Echo. Les six états spécifiques de la schizophrénie ont été définis : le premier épisode (FE), l'état de dépendance faible (LDS), l’état de dépendance élevée (HDS), l’état stable (Stable), l’état de bien-être (Well) et l'état de décès (Death). Pour évaluer les facteurs associés au risque de se trouver dans chacun des états spécifiques de la schizophrénie, nous avons construit 4 fonctions de risque en se basant sur l'analyse de risque proportionnel de Cox pour des risques compétitifs. Pour le deuxième objectif, nous avons élaboré et validé un modèle de Markov avec microsimulations de Monte-Carlo intégrant les six états spécifiques de la schizophrénie. Dans le modèle, chaque sujet avait ses propres probabilités de transition entre les états spécifiques de la schizophrénie. Ces probabilités ont été estimées en utilisant la méthode de la fonction d'incidence cumulée. Pour le troisième objectif, nous avons utilisé le modèle de Markov développé précédemment. Ce modèle inclut les coûts directs de soins de santé, estimés en utilisant les bases de données de la Régie de l'assurance maladie du Québec et Med-Echo, et les coûts directs autres que pour les soins de santé, estimés à partir des enquêtes et publications de Statistique Canada. Résultats : Un total de 14 320 personnes nouvellement diagnostiquées avec la schizophrénie ont été identifiées dans la cohorte à l'étude. Le suivi moyen des sujets était de 4,4 (± 2,6) ans. Parmi les facteurs associés à l’évolution de la schizophrénie, on peut énumérer l’âge, le sexe, le traitement pour la schizophrénie et les comorbidités. Après une période de cinq ans, nos résultats montrent que 41% des patients seront considérés guéris, 13% seront dans un état stable et 3,4% seront décédés. Au cours des 5 premières années après le diagnostic de schizophrénie, le coût direct moyen de soins de santé et autres que les soins de santé a été estimé à 36 701 $ canadiens (CAN) (95% CI: 36 264-37 138). Le coût des soins de santé a représenté 56,2% du coût direct, le coût de l'aide sociale 34,6% et le coût associé à l’institutionnalisation dans les établissements de soins de longue durée 9,2%. Si un nouveau traitement était disponible et offrait une augmentation de 20% de l'efficacité thérapeutique, le coût direct des soins de santé et autres que les soins de santé pourrait être réduit jusqu’à 14,2%. Conclusion : Nous avons identifié des facteurs associés à l’évolution de la schizophrénie. Le modèle de Markov que nous avons développé est le premier modèle canadien intégrant des probabilités de transition ajustées pour le profil individuel des facteurs de risque, en utilisant des données réelles. Le modèle montre une bonne validité interne et externe. Nos résultats indiquent qu’un nouveau traitement pourrait éventuellement réduire les hospitalisations et le coût associé aux établissements de soins de longue durée, augmenter les chances des patients de retourner sur le marché du travail et ainsi contribuer à la réduction du coût de l'aide sociale. / Aim: Pharmacological strategies for schizophrenia have received increasing attention due to the development of new therapies more effective, better tolerated but more expensive. Schizophrenia is a chronic illness with various states of illness. Objectives: This research program aimed: 1) to evaluate the factors associated with the risk of being in a specific state of schizophrenia in order to construct the risk functions of the course of schizophrenia modeling; 2) to develop and validate a Markov model with Monte-Carlo micro-simulations in order to simulate the natural course of patients who have been newly diagnosed with schizophrenic based upon the individual risk factors profile; and 3) to estimate the direct healthcare and non-healthcare cost of schizophrenia and to simulate clinical and economic impact of developing a new treatment, in a cohort of patients newly diagnosed with schizophrenia, over the first 5 years following their diagnosis. Methods: For the first objective of this research program, a total of 14,320 newly diagnosed patients with schizophrenia were identified based on data from the RAMQ and Med-Echo databases. Six disorder states of schizophrenia were defined: first episode (FE), low dependency state (LDS), high dependency state (HDS), Stable state (Stable), Well state (Well) and Death state (Death). To evaluate factors associated to the risk of being in each disease state, we constructed 4 risk functions based on the Cox proportional hazard analysis for competing risks. For the second objective, a Markov model with Monte-Carlo microsimulations with the six specific states of schizophrenia was developed and validated. In the model, each subject had his own probabilities of transition between specific states, which were estimated based on the cumulative incidence function. For the third objected, we used the Markov model we previously developed. The model includes direct healthcare costs estimated from the Régie de l’assurance maladie du Québec and Med-Echo databases and direct non-healthcare costs estimated from the surveys and publications of Statistics Canada. Results: A total of 14,320 individuals were identified in the study cohort as newly diagnosed patients with schizophrenia. The mean follow-up of the subjects was of 4.4 (± 2.6) years. The age, the sex, the schizophrenia treatment, and having comorbidities are factors that are associated with the schizophrenia course. After a five-year period, our results show that 41% of patients will be considered as having recovered, 13% will be in stable condition and 3.4% of patients will have died. The mean direct healthcare and non-healthcare cost of schizophrenia over the first 5 years following diagnosis was estimated $36,701 Canadian (CAN) (95% CI: 36,264 to 37,138). The direct healthcare cost accounted for 56.2% of the total cost, welfare assistance for 34.6% and long term care facilities for 9.2%. On the direct healthcare cost, hospitalisation cost accounted for 64.6%, medical cost for 11.4% and drug-related cost for 24%. In the case where a new treatment with 20% increase of effectiveness will be available, the direct healthcare and non-healthcare costs can be reduced up to 14.2%. Conclusion: We have identified factors associated with the schizophrenia’s specific states, The Markov model we have developed is the first Canadian model incorporating transition probabilities adjusted for individual risk factor profiles using real-life data. The model shows a good internal and external validity. Based on the cost estimates, our results indicate that a new treatment could possibly reduce hospitalization and long-term care facility costs while potentially enabling patients to return to active employment that would in turn contribute to the reduction of the welfare assistance cost.

Background Renal cell carcinoma (RCC) is the most common type of kidney cancer. Patients diagnosed with metastatic RCC (mRCC) have shorter overall survival compared to those diagnosed at earlier stages. Several targeted therapies, which cost from $7,000 - $16,000 per month have been approved since 2005 to treat mRCC. In addition, there is a growing interest in the use of cytoreductive nephrectomy (CN) with targeted therapies among mRCC patients. However, little is known regarding the economic burden of RCC and role of CN and prescribing patterns of targeted therapies among older mRCC patients. Objectives 1) To assess the economic burden of RCC among older adults in the targeted therapy era 2) To compare the overall survival (OS) and total healthcare cost (THC) among older mRCC patients receiving CN and targeted therapy versus patients receiving targeted therapy alone 3) To describe prescribing patterns of targeted therapies and associated OS and THC among older mRCC patients. Methods This dissertation was conducted using the Surveillance Epidemiology and End Results (SEER) - Medicare linked data. For the first objective, the study included a prevalent cohort of RCC patients from 2013, diagnosed during 2005 - 2013 and continuously enrolled in Medicare. RCC patients were matched to non-cancer beneficiaries using propensity score matching. Generalized linear models estimated the incremental healthcare costs. Incremental total healthcare cost (THC) was multiplied by the estimated number of RCC patients on Medicare to calculate the total economic burden of RCC. For the second objective, we included patients diagnosed with mRCC between 2007-2014 and compared overall survival (OS), and THC between patients who received CN + targeted therapy and targeted therapy alone. A propensity score based inverse probability of treatment weighting (IPTW) method was used to balance the two treatment groups. A Cox proportional hazard model assessed the risk for death and a GLM compared healthcare costs between the groups. For the third objective, patients with mRCC were defined as patients who were diagnosed at stage-IV or at earlier stages but were currently using targeted therapies. Further, we restricted our sample to patients who initiated targeted therapy. We described the frequencies of the most common first and second line targeted therapies. We also described OS and THC per month for clear-cell and non-clear cell mRCC for each therapy and line of therapy. Results The first study included 10,392 each of RCC and control patients. The average THC associated with RCC was $7,419. The average THC was $4,584 for patients diagnosed at stage-I, $4,727 for stage-II, $9,331 for stage-III, and $31,637 for stage-IV. The annual economic burden of RCC on Medicare was estimated to be $1.5 billion. The second study included 471 mRCC patients that received CN + targeted therapy or targeted therapy alone. The median OS from the adjusted survival curves was significantly higher (p Conclusions The economic burden of RCC varied substantially between early stage and metastatic patients. Among mRCC patients, use of CN among targeted therapy users was associated with a higher median OS and similar monthly THC over a lifetime. Sunitinib and everolimus were the most common first and second line targeted therapies among mRCC patients. The descriptive analysis suggested that OS and THC were similar across types of targeted therapy sequences.

Americans spent nearly $2.6 trillion, or $8,000 per person for medical and administrative costs in 2010. By 2015, healthcare spending in the United States increased to 5.8% reaching $3.2 trillion or $9,990 per individual. By tackling healthcare administrative costs, it is estimated that healthcare providers could reduce these costs by $20 billion yearly. This case study explored strategies for streamlining hospital administrative procedures to reduce costs. The business process reengineering model formed the conceptual framework for this study. Data were gathered through semistructured face-to-face interviews guided by open-ended questions with a purposeful sample of 4 hospital managers in Atlanta, Georgia. This study identifies important themes regarding cost reduction and hospital administration based on participant interviews. Themes included participants' unfavorable perspectives of the Spell out PPACA (PPACA) legislation, employment of physicians, PPACA reimbursement method, follow-up services, hospital administrative governance, and lack of business education. The themes comprised steps hospital managers could take to streamline administrative procedures to reduce costs. The implications for positive social change included the potential to provide strategies for streamlined processes that could lead to savings passed on to patients from low socio-economic backgrounds through accessibility to affordable healthcare services.

Syftet med uppsatsen är att undersöka hur andelen rökare av cigaretter påverkar denrökningsrelaterade sjukvårdskostnaden för den svenska vården. Studien presenterar treframtidsprognoser för den framtida andelen rökare under de kommande 15 åren. I den förstaprognosen antas andelen rökare vara på dagens nivå, sju procent, de kommande 15 åren. Iden andra prognosen minskar andelen rökare initialt och når sedan ett lägre steady-statejämfört med den första prognosen. I den sista prognosen minskar andelen rökare enligt dentrend som varit sedan 2004.För att kunna kalkylera de framtida sjukvårdskostnaderna har tillskrivningsfaktorer använtspå ett urval av rökningsrelaterade sjukdomar. Resultaten visar olika rökningsrelateradesjukvårdskostnader utifrån prognoserna. Kostnaderna i den första prognosen är konstantagenom hela prognosperioden. I den andra prognosen minskade de rökningsrelateradesjukvårdskostnaderna till år 2028, därefter var kostnaden lika stor för varje år. I den sistaprognosen halverades nästan kostnaden fram till år 2033.Slutsatsen som kan dras är att andelen rökare har en direkt påverkan på de rökningsrelateradesjukvårdskostnaderna. Utvecklingen av andelen rökare innebär en stor skillnad iprognostiserade kostnader och den bör undersökas noggrannare i framtiden för att kunna fåbättre prognoser. / The purpose of the thesis is to investigate how the proportion of cigarette smokers affects thesmoking-related healthcare cost for the Swedish healthcare. The study presents threeforecasts regarding the development of future proportion of smokers in the coming 15 yearsand the estimated healthcare costs with each scenario. In the first forecast, the proportion ofsmokers is at today's 7 percent and is expected to be constant for the next 15 years. Thesecond forecast deals with a future scenario in which the proportion of smokers decreases andthen evens out, thus reaching a lower steady-state compared to the first forecast. In the lastforecast, the proportion of smokers decreases according to the trend seen since 2004.To calculate future healthcare costs, attribution factors were used on a selection of smokingrelated diseases. The results show different smoking-related health care costs based on theforecasts. The costs of the first forecast show no significant changes. In the second forecast,smoking-related healthcare costs decreased until 2028. After that, the cost was the same foreach year. For the last forecast, the cost almost halved by 2033.The conclusion that can be drawn is that the proportion of smokers has a direct impact onsmoking-related health care costs. The difference in the proportion of smokers makes a bigdifference to the costs incurred.